News Adcendo raises $135m for cancer ADCs, and other financings Adcendo raises $135m for cancer ADCs, plus financings for Enveda, Cradle Bio, ATB Therapeutics, and 35Pharma
News Adcendo licenses Multitude anti-TF ADC in $1bn+ deal Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in variou
News Daiichi and AZ pull Dato-DXd filing in Europe too AstraZeneca and Daiichi Sankyo have decided to voluntarily withdraw their EU marketing application for Dato-DXd in lung cancer.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
